MIDEAS

Mitotic deacetylase-associated SANT domain protein · Q6PJG2 · MIDEAS on Sugi Atlas →

0 patent compounds predicted against MIDEAS, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MIDEAS by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Vorinostat in Children PHASE1/PHASE2COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer PHASE1/PHASE2COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer PHASE2UNKNOWN
Chidamide Combined With Toripalimab in Sarcoma PHASE2COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia nanRECRUITING
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN
Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer nanWITHDRAWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a MIDEAS binder may also engage these)

ProteinNameSimilarity
Q8BZ32 0.999 Q8BZ32 →
CECR2 Chromatin remodeling regulator CECR2 0.999 landscape →
Q96PN7 0.998 Q96PN7 →
Q9JL04 0.998 Q9JL04 →
Q8R5I7 0.997 Q8R5I7 →
Q9NPG3 0.996 Q9NPG3 →
Q9Y2H5 0.996 Q9Y2H5 →
KDM3B Lysine-specific demethylase 3B 0.996 landscape →
A7XYH5 0.996 A7XYH5 →
BAZ2A Bromodomain adjacent to zinc finger domain protein 2A 0.995 landscape →
Q9Y6A5 0.995 Q9Y6A5 →
CBX4 E3 SUMO-protein ligase CBX4 0.995 landscape →
Q8BHZ4 0.995 Q8BHZ4 →
Q969V6 0.995 Q969V6 →
A7XYQ1 0.995 A7XYQ1 →
NFRKB Nuclear factor related to kappa-B-binding protein 0.995 landscape →
Q7TPM1 0.995 Q7TPM1 →
O18805 0.995 O18805 →
Q7TN02 0.995 Q7TN02 →
Q6PDM1 0.995 Q6PDM1 →
P0C7T6 0.995 P0C7T6 →
A5PK23 0.995 A5PK23 →
Q9UN79 0.995 Q9UN79 →
Q5SYE7 0.995 Q5SYE7 →
O95402 0.995 O95402 →
Q0P5V2 0.994 Q0P5V2 →
E1BE02 0.994 E1BE02 →
A7XYJ6 0.994 A7XYJ6 →
P48382 0.994 P48382 →
O70405 0.994 O70405 →